Silver Spur Therapeutics
Silver Spur Therapeutics develops a peptide amphiphile micelle (PAM) delivery platform that enables precise, tissue-specific delivery of small-molecule drugs and RNA therapeutics to treat kidney and cardiovascular diseases. The modular platform is designed to reduce systemic toxicity and off-target effects while improving therapeutic efficacy. Preclinical studies demonstrate strong tolerability and long-term therapeutic effects from a single dose of miR-145 micelles for atherosclerosis.
- Biotechnology
- Healthcare Technology
- Drug Discovery & Therapeutics
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Traditional therapies, including small-molecule drugs and gene therapies, often face challenges with inefficient tissue targeting, requiring high or repeated dosing that can lead to systemic toxicity, off-target effects, and reduced patient compliance.
Solution
Silver Spur Therapeutics provides a peptide amphiphile micelle (PAM) delivery platform engineered to enable precise and efficient delivery of small molecule drugs and genetic therapeutics while reducing systemic toxicity. By improving biodistribution and tissue-specific targeting, the platform aims to unlock the full therapeutic potential of next-generation medicines. The technology delivers therapeutic agents directly to cellular drivers of kidney and cardiovascular diseases, mitigating disease at its source. The modular platform is compatible with both small molecules and RNA therapeutics, enabling adaptable and personalized treatment strategies.
Target Audience
Primary customers are biotechnology and pharmaceutical companies developing therapeutics for kidney and cardiovascular diseases, as well as clinical research partners investigating nanomedicine-based drug and gene delivery approaches.
Features
- Peptide amphiphile micelle (PAM) platform engineered for precise tissue-specific delivery to improve therapeutic efficacy while reducing off-target exposure and systemic toxicity
- Compatible with small-molecule drugs and RNA therapeutics, including microRNA (e.g., miR-145) payloads
- Designed for localized therapy targeting kidney and cardiovascular diseases, including polycystic kidney disease and atherosclerosis
- Preclinical studies demonstrate strong tolerability and safety across multiple animal models
- Published in vivo data showing long-term therapeutic effects from a single dose of miR-145 micelles for atherosclerosis